Tenax Therapeutics Inc (TENX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tenax Therapeutics Inc stock (TENX) is currently trading at $14.00. Tenax Therapeutics Inc PS ratio (Price-to-Sales) is 414.72. Analyst consensus price target for TENX is $29.57. WallStSmart rates TENX as Sell.
- TENX PE ratio analysis and historical PE chart
- TENX PS ratio (Price-to-Sales) history and trend
- TENX intrinsic value — DCF, Graham Number, EPV models
- TENX stock price prediction 2025 2026 2027 2028 2029 2030
- TENX fair value vs current price
- TENX insider transactions and insider buying
- Is TENX undervalued or overvalued?
- Tenax Therapeutics Inc financial analysis — revenue, earnings, cash flow
- TENX Piotroski F-Score and Altman Z-Score
- TENX analyst price target and Smart Rating
Tenax Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tenax Therapeutics Inc (TENX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Tenax Therapeutics Inc (TENX) Key Strengths (1)
Good growth relative to its price
Supporting Valuation Data
Tenax Therapeutics Inc (TENX) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 414.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 46.31%
Supporting Valuation Data
Tenax Therapeutics Inc (TENX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio. Valuation metrics including PEG Ratio (1.44) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (414.72), Price/Book (2.52) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -55.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -55.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TENX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TENX's Price-to-Sales ratio of 414.72x trades 78% above its historical average of 233.16x (78th percentile), historically expensive. The current valuation is 49% below its historical high of 805.69x set in Jul 2018, and 8416% above its historical low of 4.87x in Apr 2013.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tenax Therapeutics Inc (TENX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Tenax Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -13M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Tenax Therapeutics Inc.
Bottom Line
Tenax Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Tenax Therapeutics Inc(TENX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the United States and Canada. The company is headquartered in Morrisville, North Carolina.